Scientific Reports - Identification of potential VP40 inhibitor of Marburg virus through molecular docking, pharmacokinetic analysis and molecular dynamics simulation

YouTube video by Coatney

Amazon.com: REDTIGER VP40 4 Channel 360° Dash Cam, Dual STARVIS 2, 8 IR Night Vision | 4 Adjustable Lenses, 5.8GHz WiFi, 2.5K*2+1080P*2 Recording, GPS, Voice Control, Touchscreen, 24H Parking Mode, No...

Read the full paper: Subcellular Characterization of the Molecular Determinants of Ebola VP40 Trafficking and Assembly

The active site residue in pocket 1 and pocket 2 for binding of natural and commercial compound are present in c-terminal end of the target protein as represented in Supplementary File: Supplementary Fig. 1. Pocket 1 consists of 36 amino...

To date, 18 Marburg virus disease (MVD) outbreaks have been reported, most recently in Tanzania and Ethiopia. From 1998 to 2000, a large MVD outbreak in Watsa/Durba region, Democratic Republic of the Congo (DRC), resulted in 154 cases and 128 deaths. Given the public health risks posed by MARV, the lack of approved vaccines and therapeutics, and unpredictability of future outbreaks, this study aimed to assess the anti-MARV seroprevalence in Watsa/Durba.MethodsSamples collected in May 2023 (n = 313) included known MVD survivors (n = 5), close contacts (n = 22), and other residents (n = 286). A multiplexed immunoassay was used to assess seroreactivity to MARV and other pan-filovirus targets.ResultsAmong the Watsa/Durba cohort, 4.5% and 1.6% were seroreactive to MARV glycoprotein (GP) and VP40, including only 1 known MVD survivor. No significant associations were found between MARV seroreactivity and risk factors: travel to Uganda, receiving injections, or employment as a gold miner. Of those 14 MARV GP-reactive individuals, 85.7% were cross-reactive to other filoviral targets.ConclusionsThis detected seroprevalence among individuals with no known exposure history may indicate continued exposure to MARV or MARV-like antigens 25 years after the conclusion of the outbreak; cross-reactivity to pan-filovirus targets further suggest the potential for undetected cases.